Providence Capital Advisors, LLC Novo Nordisk A S Transaction History

Providence Capital Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$95.28 - $116.93 $857 - $1,052	9 New	9 $1,000
Q1 2022 May 12, 2022	SELL	$93.1 - $112.54 $66,659 - $80,578	-716 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$95.88 - $117.08 $177,282 - $216,480	-1,849 Reduced 72.09%	716 $80,000
Q2 2021 Aug 09, 2021	SELL	$67.66 - $84.76 $24,357 - $30,513	-360 Reduced 12.31%	2,565 $215,000
Q4 2020 Feb 11, 2021	BUY	$63.89 - $73.8 $186,878 - $215,865	2,925 New	2,925 $204,000
Q1 2019 May 08, 2019	SELL	$46.36 - $52.63 $25,034 - $28,420	-540 Closed	0 $0
Q1 2018 May 10, 2018	SELL	$48.49 - $58.14 $5,139 - $6,162	-106 Reduced 16.41%	540 $27,000
Q4 2017 Feb 12, 2018	BUY	$47.53 - $53.73 $30,704 - $34,709	646	646 $35,000

1,955

318M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $193B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Providence Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Providence Capital Advisors, LLC with notifications on news.